Annual Monitoring for Patients on Persistent Medications (MPM)
Identifying Attributes
Care Settings
Country
Publishing Organisation
Type of Quality Indicator
IOM Quality Dimension
Domain
Defining Attributes
Definition
This measure assesses the percentage of patients who received a least 180 treatment days of medication, and had a test to monitor for the use of that medication. The measure is a composite of two sub-indicators that evaluate angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), and diuretics (serum potassium and a serum creatinine therapeutic monitoring test) in the measurement year.
Numerator
(1) Annual monitoring for patients on ACE inhibitors or ARBs: the number of patients with at least one serum potassium and serum creatinine therapeutic monitoring test in the measurement year. (2) Annual monitoring for patients on diuretics: the number of patients with at least one serum potassium and serum creatinine therapeutic monitoring test in the measurement year. (3) Total rate: sum of the 2 numerators.
Denominator
Patients age 18 and older as of the end of the measurement year (e.g., December 31) who are on selected persistent medications (ACE Inhibitors/ARB or Diuretics.)
Exclusions
Exclude patients who use hospice services or elect to use a hospice benefit any time during the measurement year, regardless of when the services began. Exclude patients who had an acute or non-acute inpatient encounter during the measurement year.
Use of Risk Adjustment
Risk Adjustments
None
Stratifications
None
Collection and Reporting Attributes
Type of Data Collection
Data Collection Methods
Claims Data, Electronic Health Data and Electronic Health Records.